Aficamten improves peak oxygen uptake in obstructive HCM

Name: Aficamten improves peak oxygen uptake in obstructive HCM
Uploaded: 2024-07-02T06:00:00+00:00
Duration: 6 min 20 s
Description: Aficamten is a novel cardiac myosin inhibitor that targets hypercontractility in patients with obstructive HCM. Its effects were examined in the phase 3 SE

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
CME/CE
Moving the Needle in oHCM: The Era of Cardiac Myosin Inhibitors
Nosheen Reza, MD; Anjali Tiku Owens, MD
0.50 credits
- Nosheen Reza, MD
- Anjali Tiku Owens, MD
- Pieter Martens, MD, MSc, PhD
0.50 credits
ACACIA-HCM: What Do the Phase 3 Results Show?
ACACIA-HCM: What Do the Phase 3 Results Show?
ESC Congress 2026
ACACIA-HCM: What Do the Phase 3 Results Show?
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
- Florian Rader, MD
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Hypertrophic Cardiomyopathy
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS

Aficamten improves peak oxygen uptake in obstructive HCM

Recommended

Title